LinkedIn
ALOOSTA
Contact
The validity period for the approval for 25 active substances has been extended due to the delay in the re-evaluation following the application for renewal of the approval.
We limit ourselves in the presentation to the chemical active substances.
|
Active Ingredients |
Limited until |
Reference |
|
Bensulfuron |
15.8.2026 |
1) |
|
Chlormequat |
28.2.2027 |
|
|
Chlortoluron |
15.8.2026 |
|
|
Clomazon |
15.6.2025 |
|
|
Daminozid |
15.9.2025 |
|
|
Deltamethrin |
15.8.2026 |
|
|
Eugenol |
30.4.2026 |
|
|
Fludioxonil |
15.6.2025 |
|
|
Flufenacet |
15.6.2025 |
|
|
Flumetralin |
11.5.2026 |
|
|
Fosthiazat |
31.1.2027 |
|
|
Geraniol |
30.4.2026 |
|
|
MCPA |
15.8.2026 |
|
|
MCPB |
15.8.2026 |
|
|
Propaquizafop |
28.2.2027 |
|
|
Prosulfocarb |
31.1.2027 |
|
|
Quizalofop-P-ethyl |
28.2.2027 |
|
|
Quizalofop-P-tefury |
28.2.2027 |
|
|
Natrium-5-nitroguaiacolat |
31.1.2027 |
|
|
Natrium-o-nitrophenolat |
31.1.2027 |
|
|
Natrium-p-nitrophenolat |
31.1.2027 |
|
|
Sulfurylfluorid |
31.1.2027 |
|
|
Tebufenpyrad |
31.1.2027 |
|
|
Thymol |
30.4.2026 |
|
|
Tritosulfuron. |
15.7.2025 |
1) Commission Implementing Regulation (EU) 2023/1757 of 11 September 2023
These prolongations have no impact on the MRLs currently in force in the EU.
Author: Dr. Frank Mörsberger
Contact
Career